Dissipating a Slow Torture

Addex reports impact on uncontrolled movement in Parkinson's dyskinesia

While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea and dystonia components of the condition. The company now hopes to replicate that effect in a Phase II trial of lead compound ADX48621 due to start this

Read the full 570 word article

How to gain access

Continue reading with a
two-week free trial.